# Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246

> **NCT00907803** · PHASE2 · COMPLETED · sponsor: **SIGA Technologies** · enrollment: 107 (actual)

## Conditions studied

- Orthopoxviral Disease

## Interventions

- **DRUG:** ST-246 400 mg
- **DRUG:** ST-246 600 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00907803
- **Lead sponsor:** SIGA Technologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2010-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00907803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00907803, "Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00907803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*